Publications by authors named "Geke C Poolen"
Article Synopsis
- Thrombopoietin receptor agonists, like eltrombopag, are commonly used to treat immune thrombocytopenia (ITP) due to their effectiveness and tolerability, although there's concern about the risk of thrombosis.
- A study was conducted to evaluate how ITP patients respond to eltrombopag in terms of platelet function and hypercoagulability, comparing results from patients to healthy controls.
- Findings revealed that ITP patients were in a hypercoagulable state with altered platelet activity, and while eltrombopag treatment increased thrombin generation potential, these changes were not statistically significant after correction for multiple comparisons.
Background: Thrombomodulin on endothelial cells can form a complex with thrombin. This complex has both anticoagulant properties, by activating protein C, and clot-protective properties, by activating thrombin-activatable fibrinolysis inhibitor (TAFI). Activated TAFI (TAFIa) inhibits plasmin-mediated fibrinolysis.
View Article and Find Full Text PDF